{
  "id": "f292a64acc018928",
  "title": "U . S . FDA approves AKEEGA\u00ae as the first precision therapy for BRCA2 - mutated metastatic castration - sensitive prostate cancer with 54 % reduction in disease progression vs standard of care * ",
  "description": "20251213T014500Z",
  "content": "",
  "source": "marketscreener.com",
  "source_url": "https://www.marketscreener.com/news/u-s-fda-approves-akeega-as-the-first-precision-therapy-for-brca2-mutated-metastatic-castration-sen-ce7d50d8dd8ff622",
  "published_at": "20251213T014500Z",
  "fetched_at": "2025-12-14T00:25:01.294421+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "fda"
  ],
  "location": "",
  "raw_data": {
    "url": "https://www.marketscreener.com/news/u-s-fda-approves-akeega-as-the-first-precision-therapy-for-brca2-mutated-metastatic-castration-sen-ce7d50d8dd8ff622",
    "url_mobile": "",
    "title": "U . S . FDA approves AKEEGA\u00ae as the first precision therapy for BRCA2 - mutated metastatic castration - sensitive prostate cancer with 54 % reduction in disease progression vs standard of care * ",
    "seendate": "20251213T014500Z",
    "socialimage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
    "domain": "marketscreener.com",
    "language": "English",
    "sourcecountry": ""
  }
}